Acumen Pharmaceuticals, Inc. (ABOS) News
Filter ABOS News Items
ABOS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ABOS News From Around the Web
Below are the latest news stories about Acumen Pharmaceuticals Inc that investors may wish to consider to help them evaluate ABOS as an investment opportunity.
Bullish Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) insiders filled their treasuries with US$5.7m worth of stock over last yearMultiple insiders secured a larger position in Acumen Pharmaceuticals, Inc. ( NASDAQ:ABOS ) shares over the last 12... |
Comparing Acumen Pharmaceuticals (NASDAQ:ABOS) and Adverum Biotechnologies (NASDAQ:ADVM)Adverum Biotechnologies (NASDAQ:ADVM) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Valuation and Earnings This table compares Adverum Biotechnologies and Acumen Pharmaceuticals revenue, earnings per share [] |
Acumen Pharmaceuticals (NASDAQ:ABOS) Lowered to Sell at Zacks Investment ResearchZacks Investment Research cut shares of Acumen Pharmaceuticals (NASDAQ:ABOS) from a hold rating to a sell rating in a research note released on Tuesday morning, Zacks.com reports. According to Zacks, Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It involved in developing a novel disease for Alzheimer. The companys product pipeline consist ACU193. Acumen Pharmaceuticals [] |
Ocugen (NASDAQ:OCGN) versus Acumen Pharmaceuticals (NASDAQ:ABOS) Critical ContrastOcugen (NASDAQ:OCGN) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Analyst Ratings This is a summary of current recommendations and price targets for Ocugen and Acumen […] |
15 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA CapitalIn this piece, we will take a look at the top 15 pharmaceutical stocks to buy according to Peter Kolchinsky’s RA Capital. If you want to skip our introduction and take a look at the top five stocks in this list, head on over to 5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA […] |
Reviewing Ocugen (NASDAQ:OCGN) & Acumen Pharmaceuticals (NASDAQ:ABOS)Ocugen (NASDAQ:OCGN) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends. Analyst Recommendations This is a summary of current recommendations for Ocugen and Acumen Pharmaceuticals, as provided [] |
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Earnings Results, Beats Estimates By $0.07 EPSAcumen Pharmaceuticals (NASDAQ:ABOS) released its earnings results on Sunday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks consensus estimate of ($0.17) by $0.07, Fidelity Earnings reports. Shares of ABOS stock opened at $11.85 on Tuesday. The companys 50-day moving average price is $14.85. Acumen Pharmaceuticals has a 12 month [] |
Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business HighlightsAcumen’s investigational product candidate, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical trialsEnrolled first patients in INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease Closed initial public offering in July 2021, with aggregate net proceeds of $168.6 |
Acumen Pharmaceuticals to Present at Upcoming Investor ConferencesCHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company will participate in the following upcoming virtual conferences: Credit Suisse 30th Annual Healthcare Conference on Tuesday, November 9, 2021, at 9:40 AM ESTStifel 2021 Healthcare Conference on Tuesday, November 16, 202 |
Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Acumen announced dosing of first patient in INTERCEPT-AD in October 2021 and enrollment of patients with early Alzheimer’s disease is ongoing CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of |